Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23733173 | 0.85 | CA12 (0.34) | CA12CA1CA9 | |
| SCHEMBL432175 | 0.78 | CA12 (0.35) | CA12CA1CA9KMT2AALDH1A1 | |
| SCHEMBL317539 | 0.77 | CA12 (0.38) | CA12CA1CA9ALDH1A1PKM | |
| Hydrochloric Acid SCHEMBL28361628 | 0.74 | CA12 (0.37) | CA12CA1CA9ALDH1A1PKM | |
| SCHEMBL5596182 | 0.74 | CA12 (0.33) | CA12CA1CA9 | |
| SCHEMBL1314059 | 0.74 | CA12 (0.33) | CA12CA1CA9KMT2A | |
| SCHEMBL198304 | 0.73 | CA12 (0.34) | CA12CA1CA9 | |
| SCHEMBL1530917 | 0.72 | KMT2A (0.40) | KMT2A | |
| SCHEMBL20305859 | 0.72 | CA12 (0.32) | CA12CA1CA9 | |
| SCHEMBL9106733 | 0.71 | CA12 (0.33) | CA12CA1CA9ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210238155-A1 | CARBON MONOXIDE PRODRUGS FOR THE TREATMENT OF MEDICAL DISORDERS | GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2021-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210238155-A1 | CARBON MONOXIDE PRODRUGS FOR THE TREATMENT OF MEDICAL DISORDERS | PYGL, HMOX2, MB | CA12 50/4885CA1 356/4885CA9 59/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.